2. Cardiovascular Disease

Cardiovascular Disease

Cardiovascular Disease

Related Products

PDF 32.36 MB

Cardiovascular diseases (CVDs) are the leading causes of death and disability worldwide. CVDs include diseases of the heart, vascular diseases of the brain and diseases of blood vessels. Caused by atherosclerosis, coronary heart disease and cerebrovascular disease are the most common forms of CVDs. Other less common forms of CVDs include rheumatic heart disease and congenital heart disease. A large percentage of CVDs is preventable through the reduction of behavioral risk factors such as tobacco use, physical inactivity and unhealthy diet. Dietary sodium reduction can alleviate the long-term risk of cardiovascular disease events. Statin therapy is an effective intervention in both the primary and secondary preventions of CVDs in those who are at high risk.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-108306
    Moprolol 5741-22-0 98%
    Moprolol ((±)-Moprolol) is an beta-adrenergic receptor blocker, which can be used for research in essential hypertension.
    Moprolol
  • HY-108502
    KC 12291 hydrochloride 181936-98-1 98%
    KC 12291 hydrochloride is an orally active blocker of voltage-gated sodium channel (VGSC). KC 12291 hydrochloride reduces the amplitude of sustained Na+ current to exert antiischemic activity. KC 12291 hydrochloride has significant cardioprotective effect in vitro and in vivo.
    KC 12291 hydrochloride
  • HY-108555
    FR-171113 173904-50-2 98%
    FR171113 is a specific and non-peptide thrombin receptor antagonist. FR171113 exhibits the antithrombotic effects of a PAR1 antagonist. FR171113 inhibits thrombin-induced platelet aggregation with an IC50 of 0.29 μM..
    FR-171113
  • HY-108556
    RWJ-56110 252889-88-6 98%
    RWJ-56110 is a potent, selective, peptide-mimetic inhibitor of PAR-1 activation and internalization (binding IC50=0.44 uM) and shows no effect on PAR-2, PAR-3, or PAR-4. RWJ-56110 inhibits the aggregation of human platelets induced by both SFLLRN-NH2 (IC50=0.16 μM) and thrombin (IC50=0.34 μM), quite selective relative to U46619 (HY-108566). RWJ-56110 inhibits angiogenesis and blocks the formation of new vessels in vivo. RWJ-56110 induces cell apoptosis.
    RWJ-56110
  • HY-108564
    L 655240 103253-15-2 98%
    L 655240 is thromboxane antagonist. L 655240 attenuates early ischemia- and reperfusion-induced arrhythmias in a canine model of coronary artery occlusion. L 655240 also involves in cancer and autoimmune disorders.
    L 655240
  • HY-108571
    CP-775146 702680-17-9 98.70%
    CP-775146 is a selective PPARα agonist (Ki of 24.5 nM) that binds strongly to the PPARα ligand. CP-775146 has no observable affinity for PPARβ and PPARγ.CP-775146 shows hypolipidemic activity. CP-775146 efficiently alleviates obesity-induced liver damage, prevents lipid accumulation by activating the liver fatty acid β-oxidation pathway.
    CP-775146
  • HY-108572
    S26948 353280-43-0 98%
    S26948 is a specific peroxisome proliferator-activated receptor γ (PPARγ) modulator (EC50=8.83 nM) with potent antidiabetes and antiatherogenic effects. S26948 is a specific high-affinity agonist for PPARγ.
    S26948
  • HY-108582
    Y-27152 127408-30-4 98%
    Y-27152, a proagent of the KATP (Kir6) channel opener Y-26763, is a long-acting K+ channel opener with less tachycardia: antihypertensive effects in hypertensive rats and dogs in conscious state.
    Y-27152
  • HY-108665
    AR-C66096 tetrasodium 145782-74-7 98%
    AR-C66096 tetrasodium is a selective platelet P2YT receptor antagonist. AR-C66096 tetrasodium effectively blocks ADP-induced platelet aggregation. AR-C66096 tetrasodium can be used in the research of thromboembolism.
    AR-C66096 tetrasodium
  • HY-108765
    Ferric carboxymaltose 53858-86-9 98%
    Ferric carboxymaltose is an iron supplement.
    Ferric carboxymaltose
  • HY-108814
    Ecallantide 460738-38-9 98%
    Ecallantide (DX-88) is a specific plasma kallikrein inhibitor. Ecallantide inhibits the production of bradykinin. Ecallantide can be used to prevent acute attacks of angioedema.
    Ecallantide
  • HY-108991
    T-0509 96843-99-1 98%
    T-0509 ((-)-T-0509) is a selective full agonist of the β1 receptor. T-0509 activates the cAMP signaling pathway through the β1 receptor and enhances myocardial contractility.
    T-0509
  • HY-108997
    Palonidipine 96515-73-0 98%
    Palonidipine is a calcium antagonist which is potential for the therapy of angina-pectoris and hypertension.
    Palonidipine
  • HY-108998
    Bisaramil hydrochloride 96480-44-3 98%
    Bisaramil hydrochloride is an antiarrhythmic compound with activity in inhibiting free radical generation. Bisaramil hydrochloride directly blocks sodium currents and exhibits enhanced sodium channel blocking ability. Bisaramil hydrochloride inhibits isoproterenol-induced slow calcium action potentials in cardiomyocytes. Bisaramil hydrochloride reduces heart rate and prolongs the PR, QRS, and QT intervals in the electrocardiogram, showing blocking effects on sodium and potassium channels. Bisaramil hydrochloride reduces cardiac conduction velocity, increases the threshold current for capture and atrial fibrillation, and prolongs the effective refractory period. Bisaramil hydrochloride reduces ventricular arrhythmias and eliminates mortality caused by ventricular fibrillation in ischemic rat hearts.
    Bisaramil hydrochloride
  • HY-110015
    (-)-Chromanol 293B 163163-24-4 98%
    (-)-Chromanol 293B is a potent and selective inhibitor of the slow component of delayed rectifier K+ current (IKs). (-)-Chromanol 293B can be used for the research of antiarrhythmic.
    (-)-Chromanol 293B
  • HY-110140
    (E)-KN-93 phosphate 1188890-41-6 99.85%
    (E)-KN-93 phosphate is an inhibitor for Ca2+/calmodulin-dependent protein kinase II (CaMK II) with IC50 of 9 μM and 3 μM, for CaMKIIδ monomer and CaMKIIδ dodecamer. (E)-KN-93 phosphate binds competitively with Ca2+/CaM, and disrupts their interaction with CaMK II, and thus inhibits the CaMK II activation.
    (E)-KN-93 phosphate
  • HY-110161
    sst2 Receptor agonist-1 1021912-42-4 98%
    sst2 Receptor agonist-1 is a potent somatostatin receptor subtype 2 (sst2) agonist with a Ki value of 0.025 nM and a cAMP IC50 value of 4.8 nM. sst2 Receptor agonist-1 can inhibit rat growth hormone (GH) secretion and ocular neovascular lesion formation. Antiangiogenic effect.
    sst2 Receptor agonist-1
  • HY-110183
    Angiotensin A 51833-76-2 98%
    Angiotensin A is a renin–angiotensin system (RAS) peptide that causes a vasoconstrictive effect dependent on AT1 receptors. Angiotensin A elicits pressor and renal vasoconstrictor responses in normotensive and hypertensive rats.
    Angiotensin A
  • HY-110312
    JTV-519 fumarate 1883549-36-7 98%
    JTV-519 fumarate (K201 fumarate) is a Ca2+-dependent blocker of sarcoplasmic reticulum Ca2+-stimulated ATPase (SERCA) and a partial agonist of ryanodine receptors in striated muscle. JTV-519 fumarate is a cardioprotective agent with antiarrhythmic effects.
    JTV-519 fumarate
  • HY-11090A
    DPC423 292135-59-2 98%
    DPC423 is a highly potent, selective, and orally active factor Xa inhibitor with a Ki of 0.15 nM.
    DPC423
Cat. No. Product Name / Synonyms Application Reactivity